GlassScriptPhysician profile
Debra Beachy
NPI 1417236662
$579.73
in general payments reported to CMS, 2019-2025
16 companies · $87.08 in 2025
The $87.08 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.64 · 2023: $70.89 · 2024: $405 · 2025: $87.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.94 | 2023-2024 | Otezla, Repatha |
| Lilly USA, LLC | $83.27 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $82.60 | 2024-2025 | Airsupra |
| Abbvie INC. | $52.28 | 2024-2025 | |
| Novo Nordisk INC | $44.48 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.47 | 2024 | Jardiance |
| Abbott Laboratories | $26.14 | 2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $24.26 | 2024 | Gemtesa |
| Phadia US INC. | $24.12 | 2024 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2024 | |
| Pfizer INC. | $17.30 | 2024 | |
| Dexcom, INC. | $17.29 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $16.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.14 | 2024 | Xifaxan |
| Shield Therapeutics INC | $14.78 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.59 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Beachy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.